Research programme: women's health therapeutics - Crucell/Ferring

Drug Profile

Research programme: women's health therapeutics - Crucell/Ferring

Latest Information Update: 22 Feb 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Crucell
  • Class Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Female genital diseases

Most Recent Events

  • 22 Feb 2010 Discontinued - Preclinical for Gynaecological disorders in Denmark (unspecified route)
  • 22 Feb 2010 Discontinued - Preclinical for Gynaecological disorders in Netherlands (unspecified route)
  • 31 May 2005 Preclinical trials in Gynaecological disorders in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top